Featuring the COVID Symptom Tracker, a comparison between the COVID-19 and 2002–2003 SARS outbreaks, new ISMPP authorship guidance, a collaboration of international scientific advisers calling for open science, an opportunity for the NIH, viral genome sequencing efforts, the digital transformation of data sharing and future conferences. Novel coronavirus (COVID-19) symptom tracking: crowdsourced data collection via … Continue reading Weekly digest: what’s happening in open science?
During this period of social distancing and uncertainty, we at Open Pharma hope that all of our readers are staying safe and healthy. We also know that the deluge of information on the 2019 novel coronavirus disease (COVID-19) outbreak can be incredibly taxing on our mental health. Links to several wellbeing resources can be found … Continue reading Weekly digest: what’s happening in open science?
Featuring new endorsements to the Open Pharma position statement on open access, a Nature Careers podcast, a meta-review of data sharing, more on coronavirus research, data visualization techniques, the STM Association’s Research Data Year, transformative agreements and the impact of preprints. Ipsen and PLOS endorse the Open Pharma position statement! via Open Pharma Open Pharma … Continue reading Weekly digest: what’s happening in open science?
Featuring new open access deals and fee models, developments in sharing research data, the UK MRC’s commitment to disclosing clinical trial results, and insights into the peer review process and conference guidelines. New open access deal for UK institutions via Wiley A new agreement made between Wiley and Jisc allows researchers at UK institutions to … Continue reading Weekly digest: what’s happening in open science?
Featuring a win for transparency advocates in a federal lawsuit, the new ICMJE disclosure form, framework from cOAlition S on hybrid journals, inequalities in open access publishing, the future of scientific papers, ethical research practice, and clearing up the differences between Open Science and Open Access.
Featuring the debunking of ‘fake news’, cardiovascular clinical trial controversy, open data in the USA, reduced lack of funding for preprint repositories, the wait for the launch of the Projekt DEAL and Wiley flagship journal, ranking and indices in science, and questions surrounding Plan S.
Featuring stakeholder opinions on the proposed White House Executive Order on open access in the USA, a new data-sharing declaration and the introduction of a financial incentive for publishing negative results in Germany
As the Open Pharma position statement reaches over 100 endorsements, we share why open access is important for public health and hear why publishing house Frontiers has endorsed the position statement.
Featuring a new database of journal policies, the launch of an open peer review trial in Nature, a summary of one patient advocate’s involvement in cancer research and the call from 21 Nobel laureates for an immediate open access mandate
Open Pharma Members, Supporters and key advisers came together to discuss how medical publication professionals can improve the accessibility and discoverability of scientific research.